ClinicalTrials.gg
RecruitingNCT07869836Updated Nov 10, 2026

BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy

A Phase 3 interventional study of T-Bren, Dose level 1 and T-bren, Dose level 2 in Urothelial Cancer, Metastatic Urothelial Cancer and Bladder Cancer, sponsored by SystImmune Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by SystImmune Inc. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

Updated Nov 10, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 881 studies in Urinary Bladder Neoplasms with a site in United States — 162 open to participants now, 268 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.

Planned enrollment
47th of 714
520 · median 46
Started
2026
with 38 others
Phase 3
79 of 881
12 open now
Primary completion
2028-12
later than 211 of 265 live
Registered
876th of 881
by date

Among the 881 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 47th largest by planned enrollment of the 714 interventional ones that give a count, is one of 39 that started in 2026, is one of 79 in phase 3, reaches primary completion later than 211 of the 265 other live ones, and was the 876th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

162 of the 881 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 881 studies in Urinary Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.

Read the detailed description

This study is a Global Phase 3, randomized, open-label, multicenter study of T-bren for the treatment of metastatic UC. This study will assess the efficacy and safety of T-bren versus PBC in adult participants with HER2-expressing UC after progression on anti-PD-(L)1-based therapy.

03

Conditions studied

  • Urothelial Cancer
  • Metastatic Urothelial Cancer
  • Bladder Cancer
  • Bladder Cancer (BC)
  • Bladder (Urothelial, Transitional Cell) Cancer
  • Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
  • Bladder Ca
  • Bladder Cancer Recurrent
  • Bladder Cancer Stage IV
  • Urothelial Carcinoma Bladder
  • Urothelial Carcinoma Recurrent
  • Urothelial Carcinoma of the Urinary Bladder

Keywords

  • Bladder
  • Urothelial
  • ADC
  • T-bren
  • HER2
  • Metastatic
  • Second line
  • Third line
  • Targeted Therapy
  • Antibody drug conjugate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented or surgically unresectable transitional cell carcinoma (TCC) of the urothelium involving the renal pelvis, ureter, bladder, or urethra. Minor histologic variants (ie, \<50% overall) are acceptable, provided that TCC is the dominant histology.
  • Disease progression or recurrence during or following anti-PD-(L)1-based therapy.
  • Fresh or archival tumor samples.
  • Documented expression by central laboratory testing.
  • Eligible to receive carboplatin or cisplatin in combination with gemcitabine.
  • At least 1 based on v1.1.
  • An performance status (ECOG PS) of 0 to 1.
  • Adequate organ function.
  • Adequate coagulation parameters.

Exclusion criteria

Exclusion Criteria:

  • Prior topoisomerase inhibitor-based ADC therapy.
  • Primary tumors in the central nervous system (CNS), active or untreated , or carcinomatous meningitis.
  • Bladder cancers with small cell histology.
  • Other prior or concurrent except for certain localized cancers or low-grade prostate cancer (if approved by sponsor), or other malignancy treated with curative intent with a disease-free interval of at least 3 years.
  • Prior history of bleeding, or perforation of the gastrointestinal tract within 6 months of randomization.
  • Active diseases and inflammatory diseases.
  • History of noninfectious interstitial lung disease (ILD)/pneumonitis that required treatment with , have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
  • Advanced/clinically significant lung disease (eg, poorly controlled or asthma, restrictive lung disease, or pulmonary hypertension) within 6 months prior to randomization.
  • Known infection.
  • Active virus (HBV) infection.
  • Active virus (HCV) infection.
  • Active or latent tuberculosis.
  • Other protocol-specified inclusion/ exclusion criteria apply
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Arm A, T-bren Dose Level 1

    T-bren administered intravenously

    Drug: T-Bren, Dose level 1

  • Experimental
    Arm B, T-bren Dose Level 2

    T-bren administered intravenously

    Drug: T-bren, Dose level 2

  • Active comparator
    Arm C, Control Arm, Platinum-based Chemotherapy (PBC)

    1. Gemcitabine Administered intravenously 2. Cisplatin or Carboplatin Administered intravenously

    Drug: Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)

Interventions

  • T-bren: Administered intravenously on day 1 of each 21-day cycle

    Also known as: T-Bren, BL-M07D1, Trastuzumab Brengitecan

  • TBren administered intravenously on day 1 of each 21-day cycle

    Also known as: T-Bren, BL-M07D1, Trastuzumab Brengitecan

  • DrugGemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)

    Drug page: Gemcitabine

    Gemcitabine administered intravenously on Day 1 and Day 8 of each 21-day cycle and Cisplatin or Carboplatin administered intravenously on Day 1 of each 21-day cycle

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) per RECIST v1.1 in the primary population

    Time frame: Approximately 5 years

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) in primary population

    Time frame: Approximately 5 years

  2. Progression-Free Survival (PFS) in the ITT population

    Progression-Free Survival (PFS) by BICR per RECIST v1.1 in the ITT (Intent-to-Treat) Population

    Time frame: Approximately 5 years

  3. Overall Survival (OS) in the ITT population

    Time frame: Approximately 5 years

  4. Progression-Free Survival (PFS) by Investigator Assessment

    Progression-Free Survival (PFS) by Investigator Assessment per RECIST v1.1

    Time frame: Approximately 5 years

  5. Objective Response Rate (ORR) per RECIST v1.1

    Time frame: Approximately 5 years

  6. Disease Control Rate (DCR) per RECIST v1.1

    Time frame: Approximately 5 years

  7. Duration of Response (DOR) per RECIST v1.1

    Time frame: Approximately 5 years

  8. Time to Response (TTR) per RECIST v1.1

    Time frame: Approximately 5 years

  9. Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Approximately 5 years

07

Study locations

2 of 2 sites recruiting
  • Central Georgia Cancer Center
    Macon, Georgia 31210, United States
    Recruiting
  • Central Georgia Cancer Center
    Macon, Georgia 31210, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's planned 25 months is below that.

Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Oct 13, 2026
StartEst.
Nov 2026was Sep 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Nov 2026
Nov 10, 2026
Registered
First appeared on the registry
Oct 13, 2026
Show all 2 updates
  1. Nov 10, 2026
    Start date Sep 2026→Nov 2026
    + 1 other change: verification date
  2. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07869836
Lead sponsor
SystImmune Inc.
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Christine LaRock
Contact
Christine.LaRock@systimmune.com
425-453-6841
Jimmy Liu Zhao, MD, PhD
study director · SystImmune Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2 Antibody-drug Conjugate BL-M07D1

Start the discussion